All Posts Tagged With: "FRX"

(FRX) Forest Laboratories Sees Positive Data on Combo Drug

Forest Laboratories, Inc. (FRX) and Almirall, S.A. recently announced positive top-line data on their chronic obstructive pulmonary disease (COPD) fixed dose combination candidate, aclidinium bromide (LAMA) and formoterol fumarate...

7May2013 | | Comments Off | Continued

(MRK) Pharma & Biotech Stock Outlook – Apr 2013 – Zacks Analyst Interviews

The pharmaceutical industry has been showing signs of recovery from one of the biggest patent cliffs in recent times. The last few quarters saw major blockbusters like Merck’s (MRK) Singulair, Pfizer’s (PFE)...

7Apr2013 | | Comments Off | Continued

(FRX) Synergy Pharmaceuticals Shows Pipeline Progress

Synergy Pharmaceuticals (SGYP) recently initiated a phase IIb study with plecanatide for the treatment of patients suffering from constipation-predominant irritable bowel syndrome (IBS-C). Synergy Pharma will be enrolling 350...

1Jan2013 | | Comments Off | Continued

(MRK) Pharmaceuticals and Biotech Stock Outlook – December 2012 – Industry Outlook

The pharmaceutical industry is slowly showing signs of recovery from one of the biggest patent cliffs in recent times. The last few quarters saw major blockbusters like Merck’s (MRK) Singulair, Pfizer’s...

7Dec2012 | | Comments Off | Continued

(AZN) AstraZeneca’s Zinforo Gets European Commission Approval

AstraZeneca (AZN) recently announced that the European Commission (EC) has approved Zinforo (ceftaroline fosamil) for treating adults with complicated skin and soft tissue infections (cSSTI) or community acquired pneumonia (CAP). The...

31Aug2012 | | Comments Off | Continued

(MNOV) MediciNova’s MN-221 Yields Positive Data

MediciNova, Inc. (MNOV) recently announced positive preliminary results on intravenous MN-221 (bedoradrine). The randomized, placebo-controlled phase Ib trial evaluated the efficacy and safety of MN-221 in patients with stable, moderate-to-severe...

26Aug2012 | | Comments Off | Continued

(PFE) Pharma and Biotech Stock Outlook – August 2012 – Industry Outlook

The pharmaceutical industry is in the midst of one of the biggest patent cliffs with Pfizer’s (PFE) multi-billion-dollar blockbuster drug Lipitor losing patent protection in the US in late November 2011. Besides Lipitor, other major...

10Aug2012 | | Comments Off | Continued

(TEVA) Teva Pharmaceutical Industries Active on the Generics Front

Teva Pharmaceutical Industries Ltd. (TEVA) has been pretty active on the generic product launch front with the company launching several generic products in the last few weeks. Among recently launched generic products are Teva’s...

9Apr2012 | | Comments Off | Continued

(FRX) Forest Laboratories and Janssen Pharmaceutica Sue Generic Players

Forest Laboratories, Inc. (FRX) and Janssen Pharmaceutica NV, a Johnson & Johnson (JNJ) company, recently filed a joint lawsuit against several generic companies...

19Mar2012 | | Comments Off | Continued

(FRX) Forest Laboratories Earns Positive News on Pipeline

Forest Laboratories, Inc. (FRX) recently reported back-to-back positive news on the pipeline front. The company and partner Gedeon Richter Plc. announced that their late-stage anti-psychotic candidate, cariprazine, met its primary...

6Mar2012 | | Comments Off | Continued

(FRX) Forest Laboratories Learns of Positive Results on Gedeon Drug

Forest Laboratories, Inc. (FRX) and partner Gedeon Richter recently presented positive top-line results on their antipsychotic candidate, cariprazine (RGH-188). Preliminary top-line results were presented from a phase III study that...

13Feb2012 | | 0 comments | Continued

(JNJ) Pharma & Biotech Stock Review & Outlook – Industry Outlook

With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between...

29Dec2011 | | 0 comments | Continued

(TEVA) Teva Pharmaceutical Industries Provides In-Line 2012 Outlook

Teva Pharmaceutical Industries Ltd. (TEVA) recently provided guidance for 2012. The company expects to earn $5.48 and $5.68 per share on total net sales of about $22 billion. Guidance was generally in line with expectations. While...

27Dec2011 | | 0 comments | Continued

(EU) Emerging Markets: The Way Forward

According to Irish orator, philosopher, & politician Edmund Burke, change is the most powerful law of nature. The winds of change seem to be sweeping across the pharmaceutical industry as well. Until recently, most commercialization efforts were focused on the U.S. — the largest pharmaceutical...

7Dec2011 | | 0 comments | Continued

(AAPL) A Busy Week Ahead – Earnings Preview

Earnings Preview 10/14/11 While the earnings season kicked off this past week, only 38 firms reported. The game really gets under way next week, when we will get reports from 336 firms, including 99 members of the S&P 500. Thus, by the end of the week we will have a very good idea...

17Oct2011 | | 0 comments | Continued

(EU) Pharmaceuticals Stock Outlook – September 2011 – Industry Outlook

The pharmaceutical industry continues to be impacted by major issues such as sluggish prescription trends, European Union (EU) pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to witness a significant imbalance between new product...

23Sep2011 | | 0 comments | Continued

(AAPL) 2011 Second Quarter Earnings Preview – Detailed

Earnings Preview 7/15/11 Second quarter earnings season is now under way, but things really start to move into high gear next week. There will be 348 firms reporting, and 108 of those are in the S&P 500. By next...

18Jul2011 | | 0 comments | Continued

(FRX) Forest Laboratories Announces Viibryd Launch

Forest Laboratories, Inc. (FRX) recently announced the launch of Viibryd (vilazodone HCl) tablets in the US. Viibryd, which is approved for the treatment of adults with major depressive disorder, is available at pharmacies across the...

6Jul2011 | | 0 comments | Continued

(FRX) Forest Laboratories Seeks FDA Nod for COPD Drug

Forest Laboratories, Inc. (FRX) and partner Almirall, S.A. recently announced the submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for their chronic obstructive pulmonary disease (COPD) candidate,...

1Jul2011 | | 0 comments | Continued

(PFE) Pfizer’s Lyrica Holds Promise

Pfizer Inc. (PFE) recently presented positive top-line data on its blockbuster drug, Lyrica. Pfizer said that Lyrica met the primary endpoint in a study that was being conducted in patients with chronic central neuropathic pain following...

26Jun2011 | | 0 comments | Continued

(THRX) Theravance Analyst Maintains Neutral on Shares

We have maintained our Neutral recommendation on Theravance, Inc. (THRX) with a target price of $24.00 per share following the announcement of first quarter 2011 financial results. Theravance’s first quarter 2011 loss per...

14Jun2011 | | 0 comments | Continued

(JNJ) Pharma & Biotech Stock Outlook – June 2011 – Industry Outlook

Challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts continue to impact the pharmaceutical industry. The next five years are expected to reflect a significant imbalance between new product introductions...

14Jun2011 | | 0 comments | Continued

(THRX) Theravance Analyst Maintains Neutral Rating on Shares

We have maintained our Neutral recommendation on Theravance, Inc. (THRX) with a target price of $24.00 per share following the announcement of first quarter 2011 financial results. Theravance’s first quarter 2011 loss per...

14Jun2011 | | 0 comments | Continued

(FRX) Forest Labs Fourth Quarter 2011 Earnings Preview

Forest Labs (FRX) is all set to announce its fourth quarter and fiscal 2011 results on April 19. The Zacks Consensus Estimate for the fourth quarter is $1.07, representing a year-over-year increase of 28.9%. Meanwhile,...

18Apr2011 | | 0 comments | Continued

(THRX) Theravance Analyst Maintains Neutral on Shares

We are maintaining our Neutral recommendation on Theravance, Inc. (THRX) with a target price of $25.00 after the company’s fourth quarter and fiscal year 2010 financial results. Theravance’s fourth quarter 2010 loss...

2Apr2011 | | 0 comments | Continued

(AMAT) Stock Market News for February 23, 2011 – Market News

The fear gauge Volatility Index (VIX) surged to its highest level since May last year and benchmark indices suffered sharp declines on Tuesday. Unrest in the Middle East and North Africa continued as immediately after the overthrow of leaders in Egypt and Tunisia, demonstrators in Bahrain, Libya and...

23Feb2011 | | 0 comments | Continued

(BHP) Company News for February 23, 2011 – Corporate Summary

• Wal-Mart (NYSE:WMT) reported Q4 EPS of $1.34, ahead of the Zacks Consensus Estimate of $1.31 per share • Petrohawk Energy Corp. (NYSE:HK) reported Q4 EPS of $0.11, lower than the Zacks...

23Feb2011 | | 0 comments | Continued

(CYPB) Cypress Bioscience Reports Wider Loss

Cypress Bioscience, Inc. (CYPB) reported a net loss of 94 cents per share in the third quarter, significantly higher than the Zacks Consensus Estimate of a loss of 33 cents and the year ago loss of 12 cents. Despite an increase in...

25Nov2010 | | 0 comments | Continued

(SHPGY) Shire Beats Earnings Expectations – Increases Earnings Outlook

Shire plc (SHPGY) posted earnings of $1.16 per American Depositary Share (ADS) during the third quarter of 2010, beating the Zacks Consensus Estimate of 98 cents and the year-ago earnings of 49 cents per ADS. Higher revenues accounted...

24Nov2010 | | 0 comments | Continued

(JNJ) Pharma & Biotech Industry Outlook – November 2010 – Industry Outlook

With 2010 coming to an end, the pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product...

15Nov2010 | | 0 comments | Continued